According to the latest studies, ARID1A deficiency may be a novel biomarker for cancer immunotherapy (Shen et al. 2018; Jiang et al. 2020), and patients with ARID1A deficiency could benefit from ICIs treatment (Okamura et al. 2020). This evidence concerns the gene ARID1A and cancer.